Dapahelsun Tablet 10 mg (Dapagliflozin Anhydrous Mixture)
Dapagliflozin Anhydrous Lactose Mixture 15.27mg
Tablet · Prescription medication
Ellison Pharmaceuticals Co., Ltd.
MFDS item code 202005375 · Approved 2020.07.23
This product's status changed to Expired on 2025.07.23. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of glycemic control in type 2 diabetes mellitus
This drug is used in conjunction with dietary and exercise recommendations to help control blood sugar levels in patients with type 2 diabetes. It can be used alone or in combination with other medications. In particular, it can help prevent the occurrence of cardiovascular events in patients whose blood sugar is not adequately controlled and who have cardiovascular disease or risk factors. For more information, please refer to professional instructions. This drug is effectively used for the treatment of type 2 diabetes.
Type 2 diabetes mellitus Monotherapy and add-on combination therapy The recommended dose of this drug is 10mg once daily for monotherapy and add-on combination therapy with other glucose-lowering agents, such as insulin. When this drug is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. Initial combination therapy For patients who have not previously received pharmacological treatment for diabetes, when this drug is administered in combination with metformin, the recommended initial dose is 5mg once daily or 10mg once daily. Special populations Renal impairment - eGFR below 45 mL/min/1.73m2: Administration of this drug is not recommended for the purpose of improving glycemic control. - Patients on dialysis: Do not administer this drug. Hepatic impairment No dose adjustment is required in patients with mild or moderate hepatic impairment. For patients with severe hepatic impairment, 5 mg is recommended as the starting dose. If well tolerated, this dose may be increased to 10mg. Elderly patients (≥ 65 years) Dose adjustment based on age is not recommended. Method of administration This drug may be administered orally once daily at any time of day, with or without food. The tablet should be swallowed whole.
The efficacy and safety of dapagliflozin in children under 18 years of age have not been established. No relevant data are available.
This drug should not be used in patients who have had an allergic reaction to the active ingredient or excipients. It should also not be administered to patients with type 1 diabetes or diabetic ketoacidosis. Moreover, patients with issues related to lactose breakdown, certain genetic disorders, and those on dialysis should not use this drug. It should be administered cautiously to patients with reduced fluid volume or impaired kidney function, as hypotension or changes in kidney function may occur. Patients allergic to the dyes Yellow No. 4 and Yellow No. 5 should also be careful. This drug may increase the risk of genital infections and urinary tract infections, and immediate treatment should be sought if symptoms of infection appear. Because of the risk of hypoglycemia, dosage adjustments may be necessary when used in combination with medications that cause hypoglycemia, such as insulin or sulfonylureas. Symptoms of dehydration or hypotension may occur due to reduced fluid volume, so caution is necessary, particularly for older adults or patients on diuretics. This drug may cause a serious metabolic condition called diabetic ketoacidosis; consult healthcare professionals immediately if related symptoms occur. It is recommended that pregnant or breastfeeding women do not use this drug. The safety and effectiveness of this drug in children or adolescents have not been established, so caution is advised. There is no specific antidote in case of overdose, and appropriate treatment should be provided based on symptoms. This drug does not significantly affect driving or machine operation, but caution should be exercised due to the possibility of hypoglycemic symptoms. This drug must be kept out of the reach of children, and it is safest to store it in its original container.
Not everyone experiences these, and they can vary from person to person.
This drug should be stored in a tightly closed container to avoid exposure to air or moisture, ideally at room temperature between 1 to 30 degrees Celsius. This way, the effectiveness of the drug can be maintained for a longer period.
Yellow, convex diamond-shaped film-coated tablet
28 tablets/box [14 tablets/PTP x 2, 7 tablets/PTP x 4]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Dapagliflozin Anhydrous Lactose Mixture 15.27mg
Tablet · Prescription medication
Ellison Pharmaceuticals Co., Ltd.
Dapagliflozin Anhydrous Lactose Mixture 7.635mg
Tablet · Prescription medication
International Pharmaceuticals Co., Ltd.

Dapagliflozin Anhydrous Lactose Mixture 15.27mg
Tablet · Prescription medication
International Pharmaceutical Co., Ltd.
Dapagliflozin Anhydrous Lactose Mixture 7.635mg
Tablet · Prescription medication
Shinil Pharmaceutical Co., Ltd.

Dapagliflozin Anhydrous Lactose Mixture 15.27mg
Tablet · Prescription medication
Sinil Pharmaceutical Co., Ltd.
Dapagliflozin Anhydrous Lactose Mixture 7.635mg
Tablet · Prescription medication
Dongwha Pharmaceutical Co., Ltd.

Dapagliflozin Anhydrous Lactose Mixture 15.27mg
Tablet · Prescription medication
Donghwa Pharmaceutical Co., Ltd.
Dapagliflozin Anhydrous Lactose Mixture 7.635mg
Tablet · Prescription medication
Albozen Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.